Vanda Pharmaceuticals

Go or no go? Abbvie, Roche and Kala await key decisions

One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.

December 11, 2018

Vanda preps Hetlioz for a new market

The company hails a partial clinical trial win as the way in to a new use for Hetlioz, but the stock markets are less convinced.

November 23, 2018

Upcoming events – Vanda Pharmaceuticals awaits two catalysts and Evofem tries again

A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.

September 23, 2015

After Turing, the industry’s biggest price gougers

April 10, 2015

Good times roll in Q1 as mid and small cap winners outnumber losers

August 18, 2014

Leaders and laggards in FDA approval stakes

November 15, 2013

Despite shock adcom vote, Vanda will struggle to remain relevant

November 08, 2013

Upcoming events: FDA panel to convene over Vanda’s sleep drug

July 23, 2013

In licensing, you don’t always get what you pay for

August 29, 2012

Licensing dip claims neurology and diabetes as key victims

February 07, 2012

Merck’s new sleep drug has soporific effect on markets

Load More